EUCTR2011-004201-25-NL进行中(未招募)不适用
The BOKITO-1B Study:Tenofovir DF Bone and Kidney Toxicity. Pharmacology in HBV monoinfected patients. - BOKITO-1B
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
- Erasmus MC
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Inclusion criteria
- •Adult (> 18 years old), chronically HBV-infected, meeting the criteria for antiviral therapy
- •Group 1: 25 persons starting TDF with creatinine clearances between 50-80 mL/min
- •Group 2: 25 persons starting TDF with creatinine clearances of > 80 mL/min
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion criteria
- •Renal clearance (CG) < 50 mL/min, HIV- and/or HCV-co infection.
研究者
相似试验
尚未招募
4 期
The BOKITO-1B study: tenofovir DF bone and kidney toxicity. Pharmacology in HBV-monoinfected patients.chronic hepatitis Bviral liver infection with hepatitis B virus1001965410047438NL-OMON35480Erasmus MC, Universitair Medisch Centrum Rotterdam50
尚未招募
4 期
The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity.;Incidence and reversibility in HBV-monoinfected patients.chronic hepatitis BNL-OMON35281Erasmus MC, Universitair Medisch Centrum Rotterdam180
进行中(未招募)
不适用
The BOKITO-2B Study: Tenofovir DF Bone and Kidney Toxicity in patients with viral liver infection with hepatitis B virus. Incidence and reversibility.Chronic hepatitis BEUCTR2011-004272-11-NLErasmus MC
进行中(未招募)
不适用
Evaluation of the effects of medication for the control of chronic Hepatitis B and its effects on bone healthC02.256.430.400Hepatitis BRBR-6f4x7pFaculdade de Medicina de Ribeirão Preto da Universidade de São Paulo
已完成
2 期
Effect of Tenofovir DF on Bone Metabolism in ChildrenHIV InfectionsNCT00088309National Cancer Institute (NCI)50
